2018 American Transplant Congress
Single-Dose Basiliximab Induction in Liver Transplant Recipients with Delayed CNI Initiation
Liver transplant recipients (LTR) with peri-operative renal injury benefit from a delayed CNI protocol using basiliximab (IL2RA) induction to reduce early CNI exposure. Existing literature…2018 American Transplant Congress
The BEST Trial: A Prospective Randomized Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression
Previous large multicenter belatacept (BELA)-based CNI- and steroid-free immunosuppressive trials have not enrolled to completion due to safety concerns. The BEST Trial (Belatacept-based Early Steroid…2018 American Transplant Congress
Autologous Adipose-Derived Stem Cells with In Vivo Immunomodulatory Properties Can Be Generated in Allograft Recipients under Immunosuppression
PurposeTo determine if it is possible to generate mesenchymal stem cells (MSC) with potent in vivo immunomodulatory properties in allograft recipients under immunosuppression, we analyzed…2018 American Transplant Congress
CD40 Signaling in Proximal Tubules Regulates Fibrosis in Both Hypertension and Chronic Allograft Rejection
University of Toledo College of Medicine and Life Sciences, Toledo, OH.
Background: We explored the role of CD40 signaling in kidney proximal tubule epithelial cells on renal interstitial fibrosis (IF) in two models: hypertension; and chronic…2018 American Transplant Congress
Long Term Histologic Allograft Health is Preserved Despite Rejection during Protocolized Immunosuppression Withdrawal (ISW) in Stable Pediatric Liver Transplant Recipients
Background: Long term allograft health after rejection during ISW has not been previously assessed. We compare baseline and 4yr graft histology of 20 rejectors in…2018 American Transplant Congress
A Pre-Transplant Blood-Based Lipid Signature for Prediction of Antibody-Mediated Rejection in Kidney Transplant Patients
Virginia Commonwealth University, Richmond.
BACKGROUNDThere is a lack of biomarkers for pre-kidney transplant immune risk stratification to avoid over- or under-immunosuppression. Since the circulating lipidome is integrally involved in…2018 American Transplant Congress
Clinical Response to Salvage Bortezomib Therapy for Antibody Mediated Rejection and Mixed Acute Rejection in a High Immunologic Risk Renal Transplant Population
University of Illinois at Chicago, Chicago, IL.
Background: Proteasome inhibitor (PI) containing regimens treat antibody mediated rejection (AMR) and mixed acute rejection (MAR) due to elimination of donor specific antibody (DSA). Commonly,…2018 American Transplant Congress
Pre-Emptive Rituximab and Intravenous Immunoglobulin (IVIg) Fail to Prevent Rejection in Kidney Transplant Recipients (KTx) with Donor Specific Antibodies (DSA)
Columbia University, New York, NY.
Introduction:IVIg and Rituximab have been used successfully to improve transplantation rates in sensitized patients. DSA detected by Flow crossmatch (FXM+) or Luminex® at time of…2018 American Transplant Congress
Comparative Analysis of Alloantigen-Stimulated Gene Expression in HIV(+) Liver Transplant Rejectors versus Non-Rejectors
Surgery, University of California, San Francisco, San Francisco, CA.
In a multi-center, prospective trial of solid-organ transplantation in persons with HIV, recipients had a 2-3x increased rejection rate when compared to historical data on…2018 American Transplant Congress
Urinary Proteomics as a Dignostic Mean for Chronic Humoral Rejection after Pediatric Kidney Transplantation
Chronic antibody-mediated rejection (cAMR) is the main cause of long-term graft loss and presents a diagnostic challenge in renal transplantation medicine. Late-stage diagnosis is made…
- « Previous Page
- 1
- …
- 105
- 106
- 107
- 108
- 109
- …
- 172
- Next Page »